Melatonin to prevent delirium in patients with advanced cancer: a double blind, parallel, randomized, controlled, feasibility trial

Peter G Lawlor, Marie T McNamara-Kilian, Alistair R MacDonald, Franco Momoli, Sallyanne Tierney, Nathalie Lacaze-Masmonteil, Monidipa Dasgupta, Meera Agar, Jose L Pereira, David C Currow, Shirley H Bush, Peter G Lawlor, Marie T McNamara-Kilian, Alistair R MacDonald, Franco Momoli, Sallyanne Tierney, Nathalie Lacaze-Masmonteil, Monidipa Dasgupta, Meera Agar, Jose L Pereira, David C Currow, Shirley H Bush

Abstract

Background: Delirium is highly problematic in palliative care (PC). Preliminary data indicate a potential role for melatonin to prevent delirium, but no randomized controlled trials (RCTs) are reported in PC.

Methods: Patients aged ≥18 years, with advanced cancer, admitted to an inpatient Palliative Care Unit (PCU), having a Palliative Performance Scale rating ≥ 30%, and for whom consent was obtained, were included in the study. Patients with delirium on admission were excluded. The main study objectives were to assess the feasibility issues of conducting a double-blind RCT of exogenous melatonin to prevent delirium in PC: recruitment, retention, procedural acceptability, appropriateness of outcome measures, and preliminary efficacy and safety data. Study participants were randomized in a double-blind, parallel designed study to receive daily melatonin 3 mg or placebo orally at 21:00 over 28 days or less if incident delirium, death, discharge or withdrawal occurred earlier. Delirium was diagnosed using the Confusion Assessment Method. Efficacy endpoints in the melatonin and placebo groups were compared using time-to-event analysis: days from study entry to onset of incident delirium.

Results: Over 16 months, 60/616 (9.7%; 95% CI: 7.5-12.4%) screened subjects were enrolled. The respective melatonin (n = 30) vs placebo (n = 30) outcomes were: incident delirium in 11/30 (36.7%; 95%CI: 19.9-56.1%) vs 10/30 (33%; 95% CI: 17.3-52.8%); early discharge (6 vs 5); withdrawal (6 vs 3); death (0 vs 1); and 7 (23%) vs 11 (37%) reached the 28-day end point. The 25th percentile time-to-event were 9 and 18 days (log rank, χ2 = 0.62, p = 0.43) in melatonin and placebo groups, respectively. No serious trial medication-related adverse effects occurred and the core study procedures were acceptable. Compared to those who remained delirium-free during their study participation, those who developed delirium (n = 21) had poorer functional (p = 0.036) and cognitive performance (p = 0.013), and in particular, poorer attentional capacity (p = 0.003) at study entry.

Conclusions: A larger double-blind RCT is feasible, but both subject accrual and withdrawal rates signal a need for multisite collaboration. The apparent trend for shorter time to incident delirium in the melatonin group bodes for careful monitoring in a larger trial.

Trial registration: Registered on July 21st 2014 with ClinicalTrials.gov : NCT02200172 .

Keywords: Advanced cancer; Delirium; Feasibility study; Melatonin; Pilot; Prevention; Randomized controlled trial; Sleep.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
CONSORT Flow Diagram. PPS: Palliative Performance Scale; SDM: Substitute Decision Maker; IC: Informed Consent
Fig. 2
Fig. 2
Kaplan-Meier plots of cumulative incidence of delirium in study groups
Fig. 3
Fig. 3
Categorized precipitants of delirium for 20 participants with incident delirium. †Data were not recorded in this category for two participants

References

    1. Witlox J, Eurelings LS, de Jonghe JF, Kalisvaart KJ, Eikelenboom P, van Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA. 2010;304(4):443–451.
    1. Watt CL, Momoli F, Ansari MT, Sikora L, Bush SH, Hosie A, Kabir M, Rosenberg E, Kanji S, Lawlor PG. The incidence and prevalence of delirium across palliative care settings: a systematic review. Palliat Med. 2019. 10.1177/0269216319854944.
    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders: DSM-5. 5. Arlington: American Psychiatric Publishing; 2013.
    1. Breitbart W, Gibson C, Tremblay A. The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics. 2002;43(3):183–194.
    1. Gagnon B, Lawlor PG, Mancini IL, Pereira JL, Hanson J, Bruera ED. The impact of delirium on the circadian distribution of breakthrough analgesia in advanced cancer patients. J Pain Symptom Manag. 2001;22(4):826–833.
    1. Lawlor PG, Bush SH. Delirium in patients with cancer: assessment, impact, mechanisms and management. Nat Rev Clin Oncol. 2015;12(2):77–92.
    1. Graham CA, Chaves G, Harrison R, Gauthier LR, Nissim R, Zimmermann C, Chan V, Rodin G, Stevens B, Gagliese L. Health care professionals’ reports of cancer pain cues among older people with delirium: a qualitative-quantitative content analysis. J Pain Symp Manag. 2020;60(1):28–36.e21.
    1. Bush SH, Leonard MM, Agar M, Spiller JA, Hosie A, Wright DK, Meagher DJ, Currow DC, Bruera E, Lawlor PG. End-of-life delirium: issues regarding recognition, optimal management, and the role of sedation in the dying phase. J Pain Symptom Manag. 2014;48(2):215–230.
    1. Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol. 2012;30(11):1206–1214.
    1. Irwin SA, Pirrello RD, Hirst JM, Buckholz GT, Ferris FD. Clarifying delirium management: practical, evidenced-based, expert recommendations for clinical practice. J Palliat Med. 2013;16(4):423–435.
    1. Neufeld KJ, Yue J, Robinson TN, Inouye SK, Needham DM. Antipsychotic medication for prevention and treatment of delirium in hospitalized adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2016;64(4):705–714.
    1. Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2018;6(6):Cd005594.
    1. Finucane AM, Jones L, Leurent B, Sampson EL, Stone P, Tookman A, Candy B. Drug therapy for delirium in terminally ill adults. Cochrane Dat Syst Rev. 2020;1(1):Cd004770.
    1. Agar MR, Lawlor PG, Quinn S, Draper B, Caplan GA, Rowett D, Sanderson C, Hardy J, Le B, Eckermann S, et al. Efficacy of Oral Risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med. 2017;177(1):34–42.
    1. Bush SH, Lawlor PG, Ryan K, Centeno C, Lucchesi M, Kanji S, Siddiqi N, Morandi A, Davis DHJ, Laurent M, et al. Delirium in adult cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv143–iv165.
    1. Hshieh TT, Yang T, Gartaganis SL, Yue J, Inouye SK. Hospital elder life program: systematic review and meta-analysis of effectiveness. Am J Geriatr Psychiatry. 2018;26(10):1015–1033.
    1. Martinez F, Tobar C, Hill N. Preventing delirium: should non-pharmacological, multicomponent interventions be used? A systematic review and meta-analysis of the literature. Age Ageing. 2015;44(2):196–204.
    1. Gagnon P, Allard P, Gagnon B, Merette C, Tardif F. Delirium prevention in terminal cancer: assessment of a multicomponent intervention. Psycho-Oncology. 2012;21(2):187–194.
    1. Bosisio M, Caraceni A, Grassi L. Phenomenology of delirium in cancer patients, as described by the memorial delirium assessment scale (MDAS) and the delirium rating scale (DRS) Psychosomatics. 2006;47(6):471–478.
    1. Meagher DJ, Moran M, Raju B, Gibbons D, Donnelly S, Saunders J, Trzepacz PT. Phenomenology of delirium. Assessment of 100 adult cases using standardised measures. Br J Psychiatry. 2007;190:135–141.
    1. Maldonado JR. Neuropathogenesis of delirium: review of current etiologic theories and common pathways. Am J Geriatr Psychiatry. 2013;21(12):1190–1222.
    1. Cipolla-Neto J, Amaral FGD. Melatonin as a hormone: new physiological and clinical insights. Endocr Rev. 2018;39(6):990–1028.
    1. Hanikoglu A, Kucuksayan E, Akduman RC, Ozben T. A review on Melatonin's effects in Cancer: potential mechanisms. Anti Cancer Agents Med Chem. 2018;18(7):985–992.
    1. Mahmood D. Pleiotropic effects of melatonin. Drug Res (Stuttg) 2019;69(2):65–74.
    1. Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integrative Cancer Ther. 2012;11(4):293–303.
    1. de Castro TB, Bordin-Junior NA, de Almeida EA, de Campos Zuccari DAP. Evaluation of melatonin and AFMK levels in women with breast cancer. Endocrine. 2018;62(1):242–249.
    1. Karasek M, Kowalski AJ, Suzin J, Zylinska K, Swietoslawski J. Serum melatonin circadian profiles in women suffering from cervical cancer. J Pineal Res. 2005;39(1):73–76.
    1. Mazzoccoli G, Carughi S, De Cata A, La Viola M, Vendemiale G. Melatonin and cortisol serum levels in lung cancer patients at different stages of disease. Med Sci Monit. 2005;11(6):Cr284–Cr288.
    1. Magri F, Sarra S, Cinchetti W, Guazzoni V, Fioravanti M, Cravello L, Ferrari E. Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians. J Pineal Res. 2004;36(4):256–261.
    1. Scholtens RM, van Munster BC, van Kempen MF, de Rooij SE. Physiological melatonin levels in healthy older people: a systematic review. J Psychosom Res. 2016;86:20–27.
    1. Perras B, Kurowski V, Dodt C. Nocturnal melatonin concentration is correlated with illness severity in patients with septic disease. Intensive Care Med. 2006;32(4):624–625.
    1. Seifman MA, Gomes K, Nguyen PN, Bailey M, Rosenfeld JV, Cooper DJ, Morganti-Kossmann MC. Measurement of serum melatonin in intensive care unit patients: changes in traumatic brain injury, trauma, and medical conditions. Front Neurol. 2014;5:237.
    1. Yoshitaka S, Egi M, Morimatsu H, Kanazawa T, Toda Y, Morita K. Perioperative plasma melatonin concentration in postoperative critically ill patients: its association with delirium. J Crit Care. 2013;28(3):236–242.
    1. Mo Y, Scheer CE, Abdallah GT. Emerging role of melatonin and melatonin receptor agonists in sleep and delirium in intensive care unit patients. J Intensive Care Med. 2016;31(7):451–455.
    1. Choy SW, Yeoh AC, Lee ZZ, Srikanth V, Moran C. Melatonin and the prevention and Management of Delirium: a scoping study. Front Med (Lausanne) 2017;4:242.
    1. Chen S, Shi L, Liang F, Xu L, Desislava D, Wu Q, Zhang J. Exogenous melatonin for delirium prevention: a meta-analysis of randomized controlled trials. Mol Neurobiol. 2016;53(6):4046–4053.
    1. Siddiqi N, Harrison JK, Clegg A, Teale EA, Young J, Taylor J, Simpkins SA. Interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2016;3:Cd005563.
    1. Bush SH, Lacaze-Masmonteil N, McNamara-Kilian MT, MacDonald AR, Tierney S, Momoli F, Agar M, Currow DC, Lawlor PG. The preventative role of exogenous melatonin administration to patients with advanced cancer who are at risk of delirium: study protocol for a randomized controlled trial. Trials. 2016;17:399.
    1. Cocks K, Torgerson DJ. Sample size calculations for pilot randomized trials: a confidence interval approach. J Clin Epidemiol. 2013;66(2):197–201.
    1. Ho F, Lau F, Downing MG, Lesperance M. A reliability and validity study of the palliative performance scale. BMC Palliat Care. 2008;7:10.
    1. Common Terminology Criteria for Adverse Events (CTCAE). . Accessed 27 Sept 2020.
    1. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990;113(12):941–948.
    1. Ryan K, Leonard M, Guerin S, Donnelly S, Conroy M, Meagher D. Validation of the confusion assessment method in the palliative care setting. Palliat Med. 2009;23(1):40–45.
    1. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry. 1983;140(6):734–739.
    1. Gagnon P, Allard P, Masse B, DeSerres M. Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manag. 2000;19(6):412–426.
    1. Watanabe SM, Nekolaichuk C, Beaumont C, Johnson L, Myers J, Strasser F. A multicenter study comparing two numerical versions of the Edmonton symptom assessment system in palliative care patients. J Pain Symptom Manag. 2011;41(2):456–468.
    1. Fainsinger RL, Nekolaichuk C, Lawlor P, Hagen N, Bercovitch M, Fisch M, Galloway L, Kaye G, Landman W, Spruyt O, et al. An international multicentre validation study of a pain classification system for cancer patients. Eur J Cancer. 2010;46(16):2896–2904.
    1. Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297–307.
    1. Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The memorial delirium assessment scale. J Pain Symptom Manag. 1997;13(3):128–137.
    1. Guideline on the assessment and treatment of delirium in older adults at the end of life. . Accessed 27 Sept 2020.
    1. Canadian Pharmacists Association . Compendium of pharmaceuticals and specialties (CPS) in. Ottawa: Canadian Pharmacists Association; 2014.
    1. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481–1486.
    1. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manag. 2001;22(2):672–687.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
    1. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.
    1. Hagen NA, Biondo PD, Brasher PM, Stiles CR. Formal feasibility studies in palliative care: why they are important and how to conduct them. J Pain Symptom Manag. 2011;42(2):278–289.
    1. McCaffrey N, Fazekas B, Cutri N, Currow DC. How accurately do consecutive cohort audits predict phase III multisite clinical trial recruitment in palliative care? J Pain Symptom Manag. 2016;51(4):748–755.
    1. Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol. 2010;10:67.
    1. Whitehead AL, Sully BG, Campbell MJ. Pilot and feasibility studies: is there a difference from each other and from a randomised controlled trial? Contemp Clin Trials. 2014;38(1):130–133.
    1. Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Coleman CL, Bond CM. Defining feasibility and pilot studies in preparation for randomised controlled trials: development of a conceptual framework. PloS One. 2016;11(3):e0150205.
    1. Lawlor PG, Nekolaichuk C, Gagnon B, Mancini IL, Pereira JL, Bruera ED. Clinical utility, factor analysis, and further validation of the memorial delirium assessment scale in patients with advanced cancer: assessing delirium in advanced cancer. Cancer. 2000;88(12):2859–2867.
    1. Barnes CJ, Webber C, Bush SH, McNamara-Kilian M, Brodeur J, Marchington K, Sabri E, Lawlor PG. Rating delirium severity using the nursing delirium screening scale: a validation study in patients in palliative care. J Pain Symptom Manag. 2019;58(4):e4–e7.
    1. Lawlor PG, Rutkowski NA, MacDonald AR, Ansari MT, Sikora L, Momoli F, Kanji S, Wright DK, Rosenberg E, Hosie A, et al. A Scoping Review to Map Empirical Evidence Regarding Key Domains and Questions in the Clinical Pathway of Delirium in Palliative Care. J Pain Symp Manag. 2019;57(3):661–681.e612.
    1. Ljubisavljevic V, Kelly B. Risk factors for development of delirium among oncology patients. Gen Hosp Psychiatry. 2003;25(5):345–352.
    1. Neefjes E, Van Der Vorst M, Verdegaal B, Beekman ATF, Berkhof J, Verheul HMW. Identification of patients at risk for delirium on a medical oncology hospital ward. J Clin Oncol. 2014;32(31_suppl):130. 10.1200/jco.2014.32.31_suppl.130.
    1. Zimmerman KM, Salow M, Skarf LM, Kostas T, Paquin A, Simone MJ, Rudolph J. Increasing anticholinergic burden and delirium in palliative care inpatients. Palliat Med. 2014;28(4):335–341.
    1. Agar M, Currow D, Plummer J, Seidel R, Carnahan R, Abernethy AP. Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliat Med. 2009;23(3):257–265.
    1. Campbell N, Perkins A, Hui S, Khan B, Boustani M. Association between prescribing of anticholinergic medications and incident delirium: a cohort study. J Am Geriatr Soc. 2011;59(Suppl 2):S277–S281.
    1. Moorey HC, Zaidman S, Jackson TA. Delirium is not associated with anticholinergic burden or polypharmacy in older patients on admission to an acute hospital: an observational case control study. BMC Geriatr. 2016;16(1):162.
    1. Thomas C, Hestermann U, Kopitz J, Plaschke K, Oster P, Driessen M, Mundt C, Weisbrod M. Serum anticholinergic activity and cerebral cholinergic dysfunction: an EEG study in frail elderly with and without delirium. BMC Neurosci. 2008;9:86.
    1. van Munster BC, Thomas C, Kreisel SH, Brouwer JP, Nanninga S, Kopitz J, de Rooij SE. Longitudinal assessment of serum anticholinergic activity in delirium of the elderly. J Psychiatr Res. 2012;46(10):1339–1345.
    1. Blatch-Jones AJ, Pek W, Kirkpatrick E, Ashton-Key M. Role of feasibility and pilot studies in randomised controlled trials: a cross-sectional study. BMJ Open. 2018;8(9):e022233.
    1. Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N. Validation of the delirium rating scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci. 2001;13(2):229–242.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa